Dimethyl Sulfoxide
Apexbio Technology LLC GW9662(Synonyms: GW-9662, GW 9662, 2-Chloro-5-nitro-N-phenylbenzamide, PPAR gamma antagonist GW9662), 10mM (in 1mL DMSO), CAS: 22978-25-2.
GW9662 (CAS 22978-25-2) is an antagonist of peroxisome proliferator-activated receptor gamma (PPAR ) a nuclear receptor involved in various biological processes including tumor growth and inflammation GW9662 irreversibly blocks PPAR activity by covalently modifying cysteine residues at its ligand-binding site (IC50 3 3 M) In cellular assays GW9662 inhibits proliferation of breast cancer cell lines (MCF7 MDA-MB-231 MDA-MB-468 IC50 20 30 M) Additionally GW9662 reverses the protective impact of lipopolysaccharide on kidney ischemia/reperfusion injury demonstrating its utility for studying PPAR -mediated pathways in oncology and inflammation models
Gold Biotechnology Inc DMSO, ACS Grade 10 mL
Dimethylsulfoxide (DMSO) is a very polar organic compound that is useful in organic chemistry for solubilizing organic and inorganic compounds. DMSO is also used as a cryoprotectant for cell media, preventing the formation of ice crystals, which would otherwise damage cells. DMSO can be used in PCR reactions to inhibit the self-complementation of DNA or PCR primers and increase amplification, especially for DNA sequences, which have GC rich sequences.
Apexbio Technology LLC Dinaciclib (SCH727965)(Synonyms: SCH-727965, SCH727965, Dinaciclib, MK-7965, MK7965), 10mM (in 1mL DMSO), CAS: 779353-01-4.
Dinaciclib (SCH727965 CAS 779353-01-4) is a small-molecule inhibitor targeting cyclin-dependent kinases (CDKs) specifically CDK1 CDK2 CDK5 and CDK9 It exhibits inhibitory potencies with IC50 values of 3 nM for CDK1 1 nM for CDK2 and CDK5 and 4 nM for CDK9 By suppressing CDK activity dinaciclib interrupts cell cycle progression reduces phosphorylation of retinoblastoma (Rb) protein and triggers apoptosis In addition dinaciclib interacts with the acetyl-lysine binding regions within bromodomains Currently in clinical phases I/II it demonstrates antitumor activity both in vitro and in animal models highlighting its potential applicability in oncology research
Apexbio Technology LLC Sotrastaurin (AEB071)(Synonyms: AEB071, Sotrastaurin, PKC inhibitor AEB071, PKC inhibitor Sotrastaurin, Sotrastaurin base, AEB-071), 10mM (in 1mL DMSO), CAS: 425637-18-9.
Sotrastaurin (AEB071 CAS 425637-18-9) is a small-molecule inhibitor targeting protein kinase C (PKC) with inhibitory activity against classical and novel PKC isoforms PKC plays an integral role in immune cell signaling influencing T-cell activation proliferation and cytokine synthesis Sotrastaurin blocks PKC-mediated pathways thereby suppressing T-cell activation proliferation IL-2 mRNA expression and NK-cell function as demonstrated in ex vivo lymphocyte assays Due to its immunoregulatory properties Sotrastaurin has potential therapeutic applications in autoimmune conditions including psoriasis
Apexbio Technology LLC Mitoxantrone HCl(Synonyms: Mitoxantrone hydrochloride, Novantrone, DHAD, Mitoxantrone HCl, Mitoxantrone dihydrochloride), 10mM (in 1mL DMSO), CAS: 70476-82-3.
Mitoxantrone HCl (CAS 70476-82-3) is an antineoplastic small molecule inhibitor targeting DNA topoisomerase II (Topo-II) Topo-II enzymes manage DNA topology during replication and transcription facilitating chromosome segregation and relieving torsional stress Mitoxantrone interferes with Topo-II-mediated DNA cleavage and ligation inducing double-strand DNA breaks and chromatin rearrangement thus disrupting DNA synthesis and cell cycle progression It modulates activity of immune cells including T cells B cells and macrophages Research demonstrates mitoxantrone s apoptotic or senescence-inducing effects in normal human cell models Its uses in biomedical research include studies on leukemia multiple sclerosis and pancreatic cancer cell viability
Apexbio Technology LLC Mitomycin C 10mM (in 1mL DMSO)
Mitomycin C (CAS 50-07-7) is an antibiotic compound derived from Streptomyces caespitosus or Streptomyces lavendulae exhibiting anti-cancer properties by interfering with DNA synthesis Its mode of action involves direct formation of covalent adducts with DNA impeding DNA replication In PC3 cells mitomycin C presents an EC50 of approximately 0 14 M Moreover it can potentiate apoptosis induced by TRAIL (TNF-related apoptosis-inducing ligand) through mechanisms independent of p53 modulating apoptosis-related protein expression and caspase activation Due to its cytotoxic mechanism mitomycin C continues to serve as a useful compound in cancer research particularly in apoptosis signaling studies
Apexbio Technology LLC Evacetrapib (LY2484595) 1186486-62-3 10mM (in 1mL DMSO)
Evacetrapib (LY2484595 CAS 1186486-62-3) is a potent and selective inhibitor targeting cholesteryl ester transfer protein (CETP) a regulator of lipid metabolism Evacetrapib exhibits inhibitory activity with IC50 values of 5 5 nM in assays containing recombinant human CETP and 26 nM within human plasma CETP assays In vivo oral administration at 30 mg/kg in human CETP/ApoAI double-transgenic mice significantly reduces CETP activity and elevates HDL-cholesterol concentration (ED50 5 mg/kg) Evacetrapib does not elevate blood pressure nor induce aldosterone or cortisol synthesis in model systems highlighting its potential in cardiovascular research related to coronary artery disease
Apexbio Technology LLC Fluvastatin Sodium 93957-55-2 10mM (in 1mL DMSO)
Fluvastatin Sodium (CAS 93957-55-2) is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase the rate-limiting enzyme in cholesterol biosynthesis By blocking HMG-CoA reductase activity fluvastatin reduces serum total cholesterol LDL-cholesterol and apolipoprotein B while increasing HDL-cholesterol and apolipoprotein A-I levels In research settings fluvastatin exhibits anti-atherosclerotic anti-thrombotic and antioxidant properties Studies have shown fluvastatin decreases platelet aggregation dose-dependently in vitro reducing platelet aggregation by approximately 10-15% at clinical doses (40 mg/day) Additionally fluvastatin inhibits inflammatory angiogenesis and NO production suggesting potential applications in inflammatory and cardiovascular research
Apexbio Technology LLC Meropenem 96036-03-2 10mM (in 1mL DMSO)
Meropenem is a broad-spectrum -lactam antibiotic within the carbapenem subclass characterized by bactericidal activity against both gram-positive and gram-negative organisms It primarily acts by binding to penicillin-binding proteins (PBPs) mainly PBP2 of Escherichia coli and Pseudomonas aeruginosa and PBP1 of Staphylococcus aureus thus disrupting cell wall synthesis and bacterial growth In vitro studies indicate Meropenem inhibition is effective at MIC 4 mg/L (susceptible strains) intermediate at 8 mg/L and resistant at 16 mg/L Meropenem demonstrates greater potency against gram-negative bacteria compared to Imipenem with typical IC50 values around 0 25 mg/L for anaerobic strains It is typically used in microbiological research to investigate antibiotic susceptibility bacterial resistance mechanisms and interactions with drug metabolism
Apexbio Technology LLC XL-888 1149705-71-4 10mM (in 1mL DMSO)
XL-888 (CAS 1149705-71-4) is an orally bioavailable small molecule inhibitor targeting heat shock protein 90 (HSP90) It selectively inhibits HSP90 and HSP90 with IC50 values of 22 nM and 44 nM respectively while exhibiting markedly weaker inhibition against a panel of other kinases Structural analyses indicated XL-888 binds HSP90 via hydrogen bonding interactions involving the Asp93 residue In tumor cell assays XL-888 potently suppresses proliferation with IC50 values in the range of 0 1-45 5 nM XL-888 is used in oncology research particularly for studying resistance mechanisms to targeted therapies
Apexbio Technology LLC Elesclomol (STA-4783) 488832-69-5 10mM (in 1mL DMSO)
Elesclomol (STA-4783 CAS 488832-69-5) is a small molecule identified through phenotype-based screens for apoptotic activity which induces apoptosis in cancer cells by elevating intracellular reactive oxygen species (ROS) Its primary cellular target is mitochondrial electron transport disruption of which results in rapid accumulation of oxidative stress exceeding adaptive thresholds and ultimately triggering apoptotic cell death Elesclomol demonstrates antitumor activity across diverse human tumor xenograft models and is currently studied as an investigational anticancer compound capable of extending progression-free survival
Apexbio Technology LLC GW501516 317318-70-0 10mM (in 1mL DMSO)
GW501516 is a subtype-selective synthetic agonist targeting peroxisome proliferator-activated receptor delta (PPAR ) exhibiting a Ki value of approximately 1 1 nM PPAR widely expressed in various tissues mediates cholesterol metabolism and interacts with retinoid X receptor (RXR) In cellular reporter assays utilizing a GAL4-driven system GW501516 activates PPAR -dependent transcription with an EC50 value close to 1 2 nM and demonstrates roughly 1000-fold greater selectivity toward PPAR compared to other PPAR isoforms Experimental studies in primate models of metabolic disease have shown GW501516 promotes HDL-cholesterol elevation reduces fasting triglycerides modifies LDL/VLDL particle profiles to larger forms enhances cholesterol efflux via increasing ABCA1 expression and partially reduces hyperinsulinemia without adverse effects on glucose handling GW501516 serves as a research tool for exploring the mechanisms and functions of PPAR activation in metabolic regulation
Apexbio Technology LLC PD123319 130663-39-7 10mM (in 1mL DMSO)
PD123319 (CAS 130663-39-7) is a non-peptide antagonist targeting angiotensin II (Ang II) receptors particularly the AT2 receptor subtype It binds selectively exhibiting an IC50 of 34 nM in rat adrenal assays and 210 nM in rat brain binding assays Additionally PD123319 inhibits Ang II binding to bovine adrenal glomerulosa microsomal preparations with an IC50 of 6 9 nM Its antagonistic activity leads to reduced cyclic GMP synthesis and elevated prostaglandin E2 production without altering protein tyrosine phosphorylation or thymidine incorporation mediated by Ang II PD123319 serves as a useful pharmacological tool in investigating Ang II receptor signaling pathways
Apexbio Technology LLC ICG 001 847591-62-2 10mM (in 1mL DMSO)
ICG 001 is a small molecule inhibitor of the canonical Wnt/ -catenin signaling pathway Mechanistically it competes with -catenin for interaction with CREB-binding protein (CBP) thereby selectively disrupting CBP/ -catenin-mediated transcriptional activity driven by the TCF/ -catenin complex (IC50 3 M) Experimental studies demonstrated its use in assessing CBP-dependent biological functions regulated by Wnt signaling Research applications include investigating CBP/ -catenin roles in cancer cell proliferation such as colorectal cancer cells (HCT-116 SW480) glioblastoma stem cell growth and fibrotic responses in pulmonary and dermal experimental models Additionally ICG 001 is under evaluation in clinical studies aiming at treatment of colorectal cancer and leukemia